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Abstract
Dissemination of HIV in the host involves transit of the virus and virus-infected cells across the lymphatic endothelium. HIV
may alter lymphatic endothelial permeability to foster dissemination, but the mechanism is largely unexplored. Using a
primary human lymphatic endothelial cell model, we found that HIV-1 envelope protein gp120 induced lymphatic
hyperpermeability by disturbing the normal function of Robo4, a novel regulator of endothelial permeability. HIV-1 gp120
induced fibronectin expression and integrin a5b1 phosphorylation, which led to the complexing of these three proteins, and
their subsequent interaction with Robo4 through its fibronectin type III repeats. Moreover, pretreatment with an active N-
terminus fragment of Slit2, a Robo4 agonist, protected lymphatic endothelial cells from HIV-1 gp120-induced
hyperpermeability by inhibiting c-Src kinase activation. Our results indicate that targeting Slit2/Robo4 signaling may
protect the integrity of the lymphatic barrier and limit the dissemination of HIV in the host.
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Introduction
HIV becomes established at mucosal sites by infecting dendritic
cells, CD4
+ T lymphocytes and macrophages in the lamina
propria after its entry. From there, virus and infected cells
disseminate via lymphatic endothelial channels to the draining
lymph nodes, and subsequently pass into the bloodstream [1–4].
An impaired lymphatic barrier may accelerate HIV dissemination.
Generally, endothelial cells do not express CD4, the major
receptor of HIV, but express varying levels of CXCR4 [5] and
CCR5 [6], the co-receptors of HIV, depending on the tissue of
origin [7]. While HIV can infect endothelial cells, its biological
importance in the pathogenesis of AIDS is unclear [8–10]. The
HIV-1 envelope glycoprotein gp120 and the HIV transactivator of
transcription (Tat) may contribute to HIV-associated vasculo-
pathy. HIV-1 gp120 induces apoptosis in endothelial cells [11,12]
and Tat stimulates angiogenesis [13,14], which is often concom-
itant with hyperpermeability. Current knowledge of the effects of
HIV-associated hyperpermeability are limited to disrupting the
integrity of vascular structures and/or enhancing inflammatory
reactions. However, these phenomena are characteristic of many
infectious diseases [15] and do not explain the unique biology of
HIV. In addition, while a pivotal role for the lymphatic system in
the pathogenesis of HIV/AIDS has been suggested [16], the
pathobiology of HIV interaction with lymphatic endothelium has
not been extensively characterized.
The Slit2/Robo4 (Roundabout 4) signaling pathway is a
recently identified regulator of endothelial permeability [17].
The Slit/Robo family members were originally discovered as axon
guidance molecules that mediate repulsive signaling mechanisms
in the central nervous system [18–20]. Recent studies from animal
models strongly implicate a central role for Slit/Robo in vascular
biology [17,21]. For example, Robo4 knockdown zebrafish
embryos have vascular sprouting defects [22], and Robo4
knockout mice display abnormal vascular hyperpermeability
[17]. Moreover, Slit2/Robo4 interactions can maintain the
integrity of the vascular network and its barrier function by
inhibiting cytokine-mediated vasculogenesis and enhanced per-
meability [17,23], and the Slit2-Robo4-paxillin-GIT1 network
inhibits neovascularization and vascular leakage [24].
Slit2 belongs to a family of three glycosylated extracellular
proteins containing at least four different motifs and sharing
cognate Robo receptors (Robo1-4) [25,26]. Slits are secreted by
midline glial cells and other tissues [19,27,28], and can be
processed by proteolytic cleavage to yield a shorter C-terminus
fragment of unknown function and a longer, active N-terminus
fragment that agonizes the Robos [29,30]. Robo4 is predom-
inantly expressed in endothelial cells, including embryonic
endothelium and tumor vascular endothelium, and shows
significant structural differences from the other Robos [26,31].
Robo4 has only two immunoglobulin (Ig) domains and two
f i b r o n e c t i nt y p eI I Id o m a i n si nt h eextracellular region, whereas
the other Robos have five and three, respectively [32,33]. The
Robo4 cytoplasmic domain also differs from the other family
members, e.g. while Robo1 has four conserved motifs in this
region, Robo4 retains only two [26]. Structure-effect studies
have revealed that the Slits bind via their N-terminal leucine-
rich repeat domain to the Robos, and that the first Ig domain of
the Robos is highly conserved and important for Slit binding
[34–36].
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cells, but the precise mechanism by which they interact with each
other remains controversial [37–39]. There are two prevailing
hypotheses for their interaction. One posits that Slit2 activates
Robo4 and initiates a signaling cascade [17,21]. Alternatively,
Slit2 may interact with Robo1, and then transactivate Robo4
[39,40].
In this study, we explored if and how HIV-1 gp120 modulates
the Slit2/Robo4 signaling pathway in primary human lung
lymphatic endothelial cells. We found that HIV-1 gp120 elevated
fibronectin levels, activated fibronectin and a5b1 integrin, and
induced a physical association between a5b1 and Robo4. This
complexing of Robo4 resulted in hyperpermeability in a lymphatic
cell monolayer; however, pretreatment with Slit2N, an active N-
terminal fragment of Slit2, inhibited significantly these HIV-1
gp120-induced effects. We suggest that the Slit2/Robo4 pathway
may play a key role in modulating HIV-1 gp120-induced
lymphatic hyperpermeability, and its manipulation may be used
to inhibit the dissemination of HIV in the host.
Results
HIV-1 gp120 Induces Hyperpermeability of a Lymphatic
Cell Monolayer
The effects of HIV-1 gp120 on vascular endothelium have been
well characterized [41–43], however, very little is known about
how HIV-1 gp120 specifically affects the lymphatic barrier. To
address this issue, we studied the effects of HIV-1 gp120 from two
different HIV-1 strains (M-gp120 which utilizes the CCR5 co-
receptor on target cells, and T-gp120 which utilizes the CXCR4
co-receptor) on lung lymphatic endothelial cells (L-LECs) in an in
vitro, vascular permeability assay. Permeability was quantified by
the translocation of FITC-conjugated Dextran particles through
an L-LEC cell monolayer seeded in the top chamber of a transwell
plate, into the bottom chamber, after incubation with specified
concentrations of M-gp120 or T-gp120. We observed a significant
increase in permeability of the lymphatic cell monolayer after
treatment with both M-gp120 and T-gp120 (Figure 1A). We then
assessed in the L-LECs, the expression of CD4 (the major receptor
for HIV-1 gp120 on target cells) and the co-receptors, CCR5 and
CXCR4, by immunohistochemistry. While we detected no
expression of CD4 or CCR5 in these cells (data not shown), we
observed a robust expression of CXCR4 on the cell surface and in
the nucleus (Figure 1B). However, inhibiting the effects of CXCR4
with a neutralizing antibody had no effect on the HIV-1 gp120-
induced permeability of the monolayer (data not shown). These
data suggest that HIV-1 gp120 induces hyperpermeability in an L-
LEC monolayer by a mechanism independent of CD4, CCR5 and
CXCR4 binding.
HIV-1 gp120 Modulates the Expression of Fibronectin
and Slit2 in L-LECs
Fibronectin is important for maintaining vascular integrity [44]
and is involved in lymphangiogenesis [45,46]. Previous studies
showed that HIV-1 gp120 can bind to fibronectin through its
heparin-binding domains, and facilitate HIV infection [47–49].
Therefore, we assessed fibronectin expression by Western blot
analysis in L-LECs and their supernatant after incubation with
various concentrations of HIV-1 gp120 (M-gp120 was used in all
experiments unless specifically stated otherwise). We observed
marked increases of fibronectin (predominantly as a dimer) in cell
lysates after treatment with HIV-1 gp120, and less pronounced
increases of soluble, monomeric fibronectin in the supernatant
(Figure 2A). We interpret our data to indicate that HIV-1 gp120
can enhance fibronectin expression in lung lymphatic endothelial
cells. Interestingly, we observed that low concentrations of gp120
(10–50 ng/ml) induced a decrease in FN secretion (vs. untreated)
as compared with higher gp120 concentrations (100–500 ng/ml).
Few experimental studies focus on gp120 at such low levels,
however, we hypothesize that the effects of gp120 at these low
concentrations may be an in vitro correlate for HIV latent infection
in vivo and a low viral load, although this has yet to be confirmed.
With the recent discovery that Slit2/Robo4 signaling regulates
endothelial permeability [17,24], and our data that demonstrate
HIV-1 gp120-induced hyperpermeability and fibronectin up-
regulation in L-LECs, we postulated that fibronectin, Slit2 and
Robo4 may be interacting to regulate lymphatic permeability after
HIV exposure. By confocal microscopy, we observed the
expression and localization of fibronectin and Robo4 in L-LECs
with or without treatment with Slit2N or HIV-1 gp120. After
stimulation with Slit2N, no co-localization of fibronectin and
Robo4 was observed (Figure 2B, middle panel). When the L-LECs
were treated with HIV-1 gp120, however, fibronectin and Robo4
displayed strong co-localization (Figure 2B, right panel). These
expression patterns and interactions were corroborated by a
Robo4 immunoprecipitation assay in which L-LECs, stimulated
with HIV-1 gp120, showed fibronectin activation (by serine/
threonine phosphorylation, Figure 2C) and a significantly
enhanced physical association between fibronectin and Robo4
(Figure 2C).
Since Slit2/Robo4 signaling is known to inhibit cytokine-
induced vascular permeability [17,23], we compared Slit2
expression in L-LECs in the presence or absence of HIV-1
gp120, a known inducer of endothelial permeability. Using a semi-
quantitative RT-PCR assay, we found that at low concentrations,
HIV-1 gp120 enhanced Slit2 expression in L-LECs, while higher
concentrations of HIV-1 gp120 inhibited the expression of Slit2
(Figure 3). The inhibition of Slit2 by HIV-1 gp120 at 250 ng/ml
and 500 ng/ml is consistent with the characterization of Slit2 as an
inhibitor of pathological hyperpermeability [24]. Taken together,
Author Summary
The most common route of HIV transmission is through
unprotected sexual contact. By this route, HIV first infects
cells in the mucous membranes of the mouth, vagina or
rectum. From the mucosa, virus and virus-infected cells
move through lymphatic endothelial channels to draining
lymph nodes where they infect various cells, including
their major target cells, CD4
+ T lymphocytes. The virus and
infected cells then transmigrate through the lymphatic
barrier, enter the blood stream, and spread throughout the
body. We found that HIV-1 gp120 compromises the
lymphatic endothelial barrier by inducing hyperperme-
ability. We hypothesize that an impaired barrier may
facilitate the dissemination of HIV. Likewise maintaining a
‘‘normal’’ barrier may help slow the dispersal of HIV,
thereby protecting the body from HIV spread and
progression after initial mucosal exposure. We demon-
strated that in lymphatic endothelium the interactions
among Robo4, Slit2, fibronectin and a5b1 integrin modu-
late the effect of HIV-1 gp120 on lymphatic permeability.
Moreover, we found that Slit2 inhibits the complexing of
Robo4 with fibronectin and protects cells from gp120-
induced hyperpermeability. These data suggest that by
interacting with Robo4, Slit2 may help maintain the
integrity of the lymphatic barrier, thereby interfering with
the dissemination of HIV beyond the draining lymph
nodes.
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cooperate in mediating permeability induced by HIV-1 gp120 in
lymphatic endothelium.
HIV-1 gp120 Induces Hyperpermeability in L-LECs
through Activation of a5b1 Integrin
When fibronectin interacts with vascular endothelium it
commonly binds to either a5b1 integrin or avb3 integrin on the
cell surface. Activation of these integrins dramatically enhances
this interaction [50]. Therefore, we examined the expression of
these two integrins in L-LECs by Western blot analysis. Since
we detected a5b1,b u tn o tavb3 in L-LECs (data not shown), we
investigated only a5b1 in subsequent experiments. We treated
L-LECs for various times with either HIV-1 gp120 or Slit2N.
By Western blotting we measured the levels of b1 phosphor-
ylation, a reflection of a5b1 activation (Figure 4A). We observed
no change in a5b1 activation after Slit2N treatment, however,
incubation with HIV-1 gp120 induced significant phosphory-
lation of b1 (Figure 4A). Furthermore, we observed co-
localization of HIV-1 gp120 and activated a5b1 integrin on
the L-LEC cell surface by confocal microscopy (Figure 4B,
‘‘Merge’’ panel).
Based on these results, we hypothesized that the physical
interaction between HIV-1 gp120 and integrin a5b1 may play a
role in HIV-1 gp120-induced effects. Therefore, we examined the
effect of blocking this interaction on lymphatic hyperperme-
ability. Using the previously described in vitro transwell perme-
ability assay, cells were pre-treated with either a neutralizing anti-
a5b1 antibody or an isotype control before incubation with M-
gp120 or T-gp120. We observed increased permeability through
the L-LEC monolayer after treatment with either of the HIV-1
gp120 isotypes (Figure 4C); pretreatment with the anti-a5b1
antibody prevented much of the increase in permeability
associated with HIV-1 gp120 (Figure 4C). These data indicate
that the increased activation of a5b1 integrin by HIV-1 gp120
and their physical association are required for HIV-1 gp120-
induced hyperpermeability of L-LECs.
Slit2N Inhibits HIV-1 gp120-Induced Lymphatic
Hyperpermeability by Blocking the Interaction between
a5b1 and Robo4
Based on the results from our expression and co-localization
studies of Slit2, Robo4, gp120, fibronectin and a5b1, we sought
to investigate further the physical interactions that contribute to
HIV-1 gp120-induced hyperpermeability, and to explore the
specific effects of Slit2 on these processes. To these ends, we
examined the physical interaction of Robo4 and a5b1 in L-LECs
after treatment with Slit2N or HIV-1 gp120 in a Robo4
immunoprecipitation assay. The basal association between
Robo4 and a5b1 integrin was not affected by the differential
expression of Slit2N (Figure 5A). However, we observed a
significant increase in this physical association after treatment
with HIV-1 gp120 (Figure 5A). We then pretreated L-LECs with
Slit2N or a negative control before incubating the cells with
HIV-1 gp120. While the association between Robo4 and a5b1
integrin appeared to peak 15 minutes after HIV-1 gp120
Figure 1. HIV-1 gp120 induces hyperpermeability of a lymphatic cell monolayer. (A) Permeability, as determined by the translocation of
FITC-conjugated dextran particles through an L-LEC monolayer in transwell chambers. Cells were incubated with M-gp120, T-gp120 or controls at
various concentrations for 18 hours. Dextran particles were added, and fluorescence assessed after 5 minutes. Permeability was calculated based on
the relative fluorescence of media in lower chambers of HIV-1 gp120-treated cells vs. the controls (‘‘0’’). Data indicate the mean 6 SD of 3
independent experiments. (*** p,0.001). (B) Immunofluorescent analysis of CXCR4 expression in L-LECs. Scale bars=20 mm. Representative images
are shown.
doi:10.1371/journal.ppat.1002461.g001
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diminished this interaction (Figure 5B). Based on these data,
we theorized that Slit2 may antagonize the effects of HIV-1
gp120 on a lymphatic cell monolayer, and therefore, may protect
lymphatic endothelium against HIV-1 gp120-induced hyperper-
meability. To test this hypothesis we utilized the L-LEC
transwell permeability assay previously described. While incu-
bation with M-gp120 and T-gp120 increased L-LEC monolayer
permeability (Figure 5C, ‘‘Control’’ bars), the extent of this HIV-
1 gp120-induced hyperpermeability was significantly inhibited
by pretreatment with Slit2N (Figure 5C, ‘‘Slit2N’’ bars). We
interpret these data to indicate that Slit2N significantly inhibits
HIV-1 gp120-induced hyperpermeability in lymphatic endothe-
lium by blocking the physical association between Robo4 and
a5b1 integrin.
Figure 2. HIV-1 gp120 modulates the expression of fibronectin and Slit2 in L-LECs. (A) Representative Western blot analysis of fibronectin
(FN) expression in L-LEC cytoplasm and supernatant. Cells were serum-starved for 1 hour and incubated with indicated concentrations of HIV-1
gp120 for 18 hours before harvesting protein. GAPDH used as loading control. (B) Robo4 and FN expression in L-LECs by confocal microscopy. L-LECs
were cultured in chamber slides and incubated with either HIV-1 gp120 (500 ng/ml), Slit2 (500 ng/ml) or a control for 15 minutes before fixing and
staining cells. Red=Robo4; Green=FN; Blue=DAPI. Scale bars=10 mm. (C) Robo4 immunoprecipitation of total and phosphorylated FN (p-Ser/Ther)
by Western blot analysis in L-LECs. Cells were incubated with either HIV-1 gp120 (500 ng/ml) or a control for 15 minutes before protein from total cell
lysates was collected for Robo4 immunoprecipitation. Membrane was stripped and reprobed for Robo4 expression as a loading control.
doi:10.1371/journal.ppat.1002461.g002
Figure 3. The differential effects of HIV-1 gp120 concentrations
on Slit2 expression in L-LECs. Representative RT-PCR analysis (DNA
gel) of Slit2 expression in L-LECs after incubation with designated
concentrations of HIV-1 gp120 for 18 hours prior to performing RT-PCR.
b-actin was amplified as an internal control.
doi:10.1371/journal.ppat.1002461.g003
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Hyperpermeability
To demonstrate that Slit2N and gp120 can induce similar
effects in various types of lymphatic endothelium, we repeated the
lymphatic permeability assay using primary human dermal
lymphatic endothelial cells (D-LECs). Similar to the results using
L-LECs, gp120 increased the permeability of D-LEC monolayers
in a dose-dependent manner, and pretreatment with Slit2N
significantly decreased the gp120-induced hyperpermeability
(Figure 6A). To confirm that the changes in permeability were
not due to the origin of the gp120, we repeated this experiment
with another M-tropic gp120 protein, gp120CM, and observed
similar effects (data not shown).
To demonstrate that the effects of the gp120 protein reflect
accurately those of intact HIV-1 virions on lymphatic hyperper-
meability, we pretreated L-LEC monolayers with Slit2N or a
negative control, followed by incubation with HIV-1 virions or
gp120. We found that HIV-1 virions significantly increased
lymphatic permeability within 5 hours, whereas gp120 induced
only a mild increase during the same time period (overnight
incubation was needed for full in vitro effect of gp120 on
permeability) (Figure 6B). Pretreatment with Slit2N significantly
inhibited the permeability induced by both the HIV-1 virions and
the gp120 protein (Figure 6B). Taken together, our results indicate
that intact HIV-1 virions increase lymphatic monolayer perme-
ability, and preincubation with Slit2N can effectively inhibit this
increase. These data indicate that HIV-1 virions can induce
lymphatic endothelial monolayer permeability similar to that
induced by gp120, suggesting that our in vitro model of gp120-
induced endothelial cell monolayer permeability may reflect the
actions of HIV-1 in vivo.
Slit2 and Robo4 Influence HIV-1 gp120-Induced
Hyperpermeability in L-LECs by Modulating c-Src Kinase
Activation and Signaling
To elucidate the signaling cascade(s) responsible for HIV-1
gp120-induced hyperpermeability in lymphatic endothelium, we
analyzed the effects of HIV-1 gp120, Slit2N and Robo4 by
Western blot analysis on Src kinase, a key molecule in the
regulation of vascular endothelial permeability [51,52]. We found
that preincubation of L-LECs with Slit2N significantly inhibited
HIV-1 gp120-induced phosphorylation of c-Src (Figure 7A),
indicating inhibition of the Src signaling pathway. We theorized
that the modulation of Src kinase signaling by Slit2N and Robo4
may be the result of a physical complexing between the two
proteins. To test this hypothesis, we transiently expressed both
Robo4 and Myc-tagged Slit2 in 293 cells, and examined their
physical association in a Robo4 immunoprecipitation assay. We
observed a physical association between Slit2 (c-Myc) and Robo4
in these cells (Figure 7B).
Figure 4. HIV-1 gp120 induces hyperpermeability in L-LECs through activation of a5b1 integrin. (A) Representative Western blot analysis
of phosphorylated a5b1 integrin in L-LECs after 2 hours of serum starvation and subsequent incubation for designated times with HIV-1 gp120
(500 ng/ml) or Slit2N (500 ng/ml). GAPDH used as loading control. (B) Phosphorylated a5b1 integrin and HIV-1 gp120 expression and co-localization
in L-LECs by confocal microscopy. L-LECs were cultured in chamber slides and incubated with HIV-1 gp120 (500 ng/ml) for 15 minutes before fixing
and staining cells. Scale bars=10 mm. (C) Permeability through an L-LEC monolayer as previously described. L-LEC monolayers were pretreated with a
neutralizing anti-integrin b1 antibody or a normal IgG control for 2 hours before incubating with M-gp120 or T-gp120 (both 500 ng/ml) for 18 hours.
Data indicate the mean 6 SD of 3 independent experiments. (**p,0.01; *** p,0.001).
doi:10.1371/journal.ppat.1002461.g004
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there appeared to be a physical association between Slit2 and
Robo4, we asked if the inhibition of c-Src signaling was a result of
Slit2 sequestering Robo4 to deplete its cellular levels and render it
unavailable for binding to a competing protein. To approximate
this situation, we pretreated L-LECs with a mixture of Robo4
siRNAs or a control siRNA before incubating the cells with HIV-1
gp120. We did not observe the same inhibition of c-Src activation
as we had with the Slit2N preincubation (Figure 7A). Instead, the
constitutive activation of c-Src increased dramatically in the
Robo4 knockdown cells as compared with the control siRNA-
transfected cells (Figure 7C). These findings are consistent with the
phenotype of Robo4 knockout mice which display heightened
vascular permeability [17]. These data suggest that a sufficient
endogenous level of Robo4 in lymphatic endothelium is necessary
to block c-Src signaling, and that its binding to Slit2 is required to
protect against lymphatic hyperpermeability. Additionally, HIV-1
gp120 did not enhance c-Src signaling in the Robo4 knockdown
cells as it did in the control siRNA-transfected cells (Figure 7C).
We hypothesize that the elevated constitutive level of c-Src kinase
signaling in the Robo4 knockdown cells prevented HIV-1 gp120
from enhancing this effect in the L-LECs.
To determine if Src signaling is involved in HIV-1 gp120-
induced lymphatic permeability, we pretreated L-LECs with a Src
kinase inhibitor or a DMSO control before measuring HIV-1
gp120-induced permeability, as described previously. While
treatment with HIV-1 gp120 resulted in increased permeability
through the L-LEC monolayer preincubated with DMSO, HIV-1
gp120 had no effect on the L-LECs preincubated with a Src kinase
inhibitor (Figure 7D). Taken together, we interpret these data to
Figure 5. Slit2N inhibits HIV-1 gp120-induced lymphatic hyperpermeability by blocking the interaction between a5b1 integrin and
Robo4. (A) Robo4 immunoprecipitation of a5b1 integrin by Western blot analysis in L-LECs. Cells were incubated with either Slit2N (500 ng/ml), HIV-
1 gp120 (500 ng/ml) or their respective controls (‘‘2’’) for 15 minutes before protein from total cell lysates was collected for Robo4
immunoprecipitation. Membranes were stripped and reprobed for Robo4 expression as a loading control. (B) Robo4 immunoprecipitation of a5b1
integrin by Western blot analysis in L-LECs. Cells were incubated with either Slit2N (500 ng/ml) or a control for 2 hours and then treated with HIV-1
gp120 (500 ng/ml) for times indicated before the protein from total cell lysates was collected for Robo4 immunoprecipitation. Membrane was
stripped and reprobed for Robo4 expression as a loading control. (C) Permeability through an L-LEC monolayer as previously described. L-LEC
monolayers were pretreated with Slit2N (500 ng/ml) or a control for 2 hours before incubating with M-gp120 or T-gp120 (both 500 ng/ml) for
18 hours. Data indicate the mean 6 SD of 3 independent experiments. (**p,0.01; *** p,0.001 for treatment with Slit2N versus vehicle control).
doi:10.1371/journal.ppat.1002461.g005
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PLoS Pathogens | www.plospathogens.org 6 January 2012 | Volume 8 | Issue 1 | e1002461indicate that Src kinase signaling is required for HIV-1 gp120-
induced lymphatic hyperpermeability, and that Slit2/Robo4
interactions can inhibit this signaling cascade.
Robo4 Expression Levels Influence Lymphatic
Hyperpermeability in L-LEC Monolayers
To characterize more precisely the role of Robo4 in HIV-1
gp120-induced effects on lymphatic permeability, we transfected
L-LECs with control siRNAs or Robo4-specific siRNAs (to reduce
Robo4 levels), and confirmed a decrease in Robo4 expression by
Western blot analysis 24 hours later (Figure 8A). We compared the
permeability of L-LEC monolayers expressing endogenous levels
of Robo4 (Figure 8B, ‘‘Control siRNA’’ columns) and reduced
levels of Robo4 (Figure 8B, ‘‘Robo4 siRNA’’ columns) in the
presence or absence of Slit2N or HIV-1 gp120. In the L-LEC
monolayers with endogenous levels of Robo4, incubation with
Slit2N had no significant effect on permeability, but HIV-1 gp120
significantly increased the permeability of this monolayer. We
observed a significantly higher basal level of permeability in the L-
LEC monolayers with reduced Robo4 levels. Slit2N had no
significant effect on the permeability of these monolayers, and
HIV-1 gp120 failed to cause any significant change in the
permeability of the L-LEC monolayers with reduced Robo4 levels.
We hypothesize that HIV-1 gp120 did not enhance the
permeability of these monolayers, because reducing Robo4 levels
had already markedly increased their permeability. These data
suggest that sufficient endogenous levels of Robo4 are required to
maintain an intact lymphatic barrier.
The Fibronectin Domains of Robo4 Are Critical for gp120-
Induced Hyperpermeability of L-LEC Monolayers
The Robo4 receptor contains two fibronectin (FN) type III
domains in its extracellular region [32,33]. While a study by Kaur
et al., demonstrated that these motifs are important for the
interaction of Robo4 with fibronectin [38], no other function for
the domains has been documented. Fibronectin regulates the
permeability of vascular endothelium [44]. We observed that
HIV-1 gp120 elevated FN levels and enhanced lymphatic
monolayer permeability in L-LECs. Therefore, we examined the
effects of fibronectin on c-Src activation, and its effects after
pretreatment with Slit2N. We observed that fibronectin enhanced
the activation of c-Src, and that pretreatment with Slit2N
significantly inhibited the FN-induced activation of c-Src
(Figure 9A). We hypothesize that Slit2N may be interacting with
Robo4 to block the FN-induced c-Src activation, and that the FN
domains of Robo4 may be involved in the inhibition of FN-
induced c-Src activation by Slit2 and L-LEC monolayer
hyperpermeability.
To explore the potential role of the Robo4 FN domains in HIV-
1 gp120-induced effects, we compared the effects of HIV-1 gp120
on the permeability of L-LEC monolayers transfected with wild-
type Robo4 (WT), mutant Robo4 (MT), which lacks the FN type
III domains, or a vector control (V). We found that HIV-1 gp120
induced significantly less permeability in L-LEC monolayers with
elevated levels of wild-type Robo4 as compared to those with
endogenous Robo4 levels (Figure 9B). These results indicate that
Robo4 inhibits HIV-1 gp120-induced permeability in L-LEC
monolayers, and may protect the integrity of the lymphatic barrier
after HIV-1 infection by interacting with Slit2. We also observed
that HIV-1 gp120-induced permeability was inhibited to a
significantly greater extent in the L-LEC monolayers transfected
with mutant Robo4 vs. wild-type Robo4. In fact, treatment with
HIV-1 gp120 resulted in no change in the permeability of the L-
LEC monolayers expressing mutant Robo4 (Figure 9B). We
interpret these results to indicate that the complexing of FN and
Robo4 (through its FN type III domains) is necessary for HIV-1
gp120-induced hyperpermeability of L-LEC monolayers, and that
the FN type III domains of Robo4 may be required for the
interaction of HIV-1 gp120, Robo4 and FN.
To explore this hypothesis, we transiently transfected L-LECs
with plasmids encoding wild-type Robo4 (WT), mutant Robo4
(MT), or a vector control (V). After 48 hours, we analyzed the
effects of HIV-1 gp120 on c-Src pathway activation in each of the
transfected cell types by Western blot analysis. We observed that
the basal level of c-Src activation was lower in L-LECs with
elevated Robo4 expression as compared to those with endogenous
Robo4 expression (Figure 9C, WT/2 and V/2, respectively).
HIV-1 gp120 increased c-Src activation in both cell types
(Figure 9C), however, overall HIV-1 gp120-induced c-Src
activation levels were significantly lower in L-LECs with elevated
Robo4 levels as compared to those with endogenous Robo4 levels
(Figure 9C, WT/+ and V/+, respectively). In L-LECs expressing
elevated levels of mutant Robo4 (MT), both basal c-Src activation
and HIV-1 gp120-induced c-Src activation were equivalent to the
L-LECs expressing elevated wild-type Robo4 (Figure 9C). These
data indicate that elevated levels of Robo4 inhibit basal c-Src
activation and HIV-1 gp120-induced c-Src activation. We
Figure 6. Slit2N attenuates HIV-1 virus-induced lymphatic
hyperpermeability. (A) Permeability through a dermal lymphatic
endothelial cell (D-LEC) monolayer as previously described. D-LEC
monolayers were pretreated with Slit2N (500 ng/ml) or a control for
2 hours before incubating with M-gp120 (500 ng/ml) for 18 hours. (B)
Permeability through an L-LEC monolayer as previously described. L-
LEC monolayers were pretreated with Slit2N (500 ng/ml) or a control for
1 hour, followed by incubation with HIV-1 virions (4.0610
6 TCID 50/ml)
or gp120 (500 ng/ml) for 5 hours. The viral load corresponds to a gp120
concentration of 425 ng/ml. For (A) and (B), data indicate the mean 6
SD of 3 independent experiments. (*p,0.05; *** p,0.001 for treatment
with Slit2N versus vehicle control).
doi:10.1371/journal.ppat.1002461.g006
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Robo4 levels after transfection may magnify the effects of Slit2, by
providing more receptors to which endogenous Slit2 can bind.
We also examined the levels of HIV-1 gp120-induced
phosphorylation of ERK1/2, key signaling molecules for endo-
thelial cell function, by Western blot analysis, using the same three
groups of L-LEC transfectants. HIV-1 gp120 induced a significant
increase in ERK1/2 phosphorylation in the L-LECs transfectants
with elevated wild-type Robo4 expression as compared to those
with endogenous Robo4 expression (Figure 9C). Although HIV-1
gp120 increased the phosphorylation of ERK1/2 in the L-LECs
transfected with mutant Robo4, the increase was significantly
Figure 7. Slit2N and Robo4 influence gp120-induced hyperpermeability in L-LECs by modulating c-Src kinase activation and
signaling. (A) Representative Western blot analysis of phosphorylated c-Src in L-LECs after preincubation with either Slit2N (500 ng/ml) or a control
for 2 hours before treatment with HIV-1 gp120 (500 ng/ml) for times indicated. GAPDH used as loading control. (B) Robo4 immunoprecipitation of
Myc-tagged Slit2 by Western blot analysis in 293 cells. 293 s were co-transfected with a Robo4 expression plasmid and either a Myc-tagged Slit2
expression plasmid or a vector control. Cells were incubated for 48 hours before the protein from total cell lysates was collected for Robo4
immunoprecipitation. (C) Representative Western blot analysis of phosphorylated c-Src in L-LECs after transfection with either Robo4-specific siRNAs
or a control siRNA for 48 hours before treatment with HIV-1 gp120 (500 ng/ml) for times indicated. GAPDH used as loading control. (D) Permeability
through an L-LEC monolayer as previously described. An L-LEC monolayer was pretreated with a Src kinase inhibitor (2 mM) or DMSO for 2 hours
before incubating with HIV-1 gp120 (500 ng/ml) or a control for 18 hours. Data indicate the mean 6 SD of 3 independent experiments. (**p,0.01 for
treatment with the Src kinase inhibitor versus DMSO control).
doi:10.1371/journal.ppat.1002461.g007
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data indicate that while the FN domains of Robo4 are not
required for the inhibition of gp120-induced c-Src activation, they
are required for gp120-induced phosphorylation of ERK1/2. We
hypothesize that the FN domains of Robo4 may participate in the
activation of other key signaling molecules like ERK1/2, however,
further investigation is needed to fully understand their function.
Discussion
The integrity of the lymphatic barrier requires a dynamic
interaction between fibronectin, other extracellular matrix (ECM)
proteins, and their receptors, cell-surface integrins [46,53]. As a
result of HIV-1-induced inflammation and increased protease
expression, fibronectin fragments are detected in the blood of
HIV-infected patients [54–56]. These fragments are believed to
promote the transendothelial migration of HIV-1-infected and
non-infected leukocytes, and to promote viral stability and cell-to-
cell transmission [48,56,57]. We found that lymphatic endothelial
cells produce elevated levels of cell-bound fibronectin after
exposure to HIV-1 gp120 (Figure 2A). This elevation appeared
to modulate the integrity of the lymphatic barrier. In particular,
HIV-1 gp120 induced activation of a5b1 integrin which enhanced
the physical complexing of HIV-1 gp120, fibronectin, a5b1
integrin and Robo4, and resulted in lymphatic hyperpermeability
(Figures 1A, 2B, 2C, 4A and 4B).
While FN/integrin [45] and Slit2/Robo4 [17] interactions are
both important for endothelial permeability, little is known about
their relationship. a5b1 and avb3 are two major integrins expressed
on the surface of endothelial cells [45]. We and others have shown
that integrin a5b1, but not avb3, clustered in focal contacts of
endothelial cells during stressful cellular conditions (Figure 4B) or
incubation with fibronectin [58–60]. In this study, we found that
Robo4 formed a complex with fibronectin and integrin a5b1 at
low, basal levels in uninfected lymphatic endothelial cells
(Figures 2B, 5A and 5B). Slit2N did not alter this association,
which is important for maintaining the integrity of the lymphatic
barrier (Figures 5A and 5C). However, exposure to HIV-1 gp120
enhanced the association of a5b1 and Robo4 (Figure 5A) and
resulted in increased lymphatic permeability (Figures 1A and 5C).
Moreover, pre-incubation with Slit2N blocked the HIV-1 gp120-
induced enhanced complexing of Robo4 and a5b1, (Figure 5B)
and lymphatic hyperpermeability was reduced (Figure 5C). These
data suggest that a5b1 integrin may also participate in the effects of
HIV-1 gp120 on lymphatic permeability, and Slit2 may help
sustain the integrity of the lymphatic barrier after HIV-1 exposure.
Activation of the Src kinases modulates cytoskeletal remodeling
and affects cell-to-cell and cell-to-ECM adhesion [61,62]. Our
data indicate that HIV-1 gp120 and Slit2 exert opposing effects on
c-Src kinase signaling, namely, HIV-1 gp120 activates c-Src
signaling, while pretreatment with Slit2N significantly reduces
these effects (Figure 7A). Moreover, the enhancement or inhibition
of Src kinase signaling and the resulting effect on lymphatic
permeability is critically dependent on Robo4 levels (Figures 9A,
9B, and 9C).
Robo4 displays unique structure and function, but the
relationship between these characteristics is largely unknown
[26,32,33]. Although the first Ig domains of the Robos are highly
conserved and important for Slit binding, direct binding of Slit2 to
Robo4 is still debated [37–39]. The Robo proteins, including
Robo4, contain fibronectin type III domains. Previous studies,
which found that the FN domains were required for adhesion to
fibronectin, suggest that these domains may play a central role in
modulating vascular permeability [38]. Our data strongly support
Figure 8. Robo4 expression levels influence HIV-1 gp120-induced lymphatic hyperpermeability. (A) Representative Western blot
analysis of Robo4 expression in L-LECs, 24 hours after transfection with a mixture of Robo4-specific siRNAs or a negative control siRNA. GAPDH used
as loading control. (B) Permeability through an L-LEC monolayer as previously described. L-LECs transfected with control siRNAs or Robo4-specific
siRNAs were seeded into the upper chamber of transwell plates and incubated with Slit2N (500 ng/ml), HIV-1 gp120 (500 ng/ml), or a control, for
18 hours. Data indicate the mean 6 SD of 3 independent experiments. (**p,0.01 for treatment with Slit2N or HIV-1 gp120 versus negative control of
the L-LECs transfected with control siRNAs).
doi:10.1371/journal.ppat.1002461.g008
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HIV-1 gp120 stimulation, and imply a potential role for Robo4 in
fibronectin-associated vasculopathies, such as HIV-associated
pulmonary hypertension [63].
Based on our new data and that of others, we propose a
hypothetical model for the interactions of HIV-1 gp120, FN, a5b1
integrin, Robo4 and Slit2, and their effect on lymphatic
permeability (Figure 10). Robo4 and a5b1 integrin are transmem-
brane proteins expressed in lymphatic endothelium. We hypoth-
esize that under normal, physiological conditions, soluble FN and
Slit2 are expressed at low, basal levels, and they interact with
Robo4 via its FN type III domains and Ig domains, respectively.
FN also binds to a5b1 integrin, which is expressed on the
endothelial cell surface. Under these conditions, the integrity of the
lymphatic endothelial barrier is intact, and transmigration through
the endothelial barrier is severely restricted. We propose that upon
HIV infection, HIV-1 gp120 elevates FN levels significantly and
complexes with FN. FN then activates a5b1 integrin, which results
in enhanced intracellular signaling through a5b1 integrin, a
significantly stronger interaction between FN and Robo4, and
enhanced intracellular signaling through Robo4. These changes
activate the c-Src signaling pathway and induce hyperpermeability
of the lymphatic endothelial barrier. The resulting ‘‘leaky’’ barrier
may facilitate the dissemination of HIV-1 and virus-infected cells
throughout the body. Furthermore, we propose that elevated levels
of Slit2 may protect the lymphatic channels from HIV-induced
vasculopathy and HIV spread. We hypothesize that at sufficiently
elevated levels, Slit2 will bind strongly to the Ig domains of Robo4
and inhibit c-Src pathway activation and HIV-1 gp120-induced
lymphatic hyperpermeability. Slit2 may affect this inhibition by
various means. A likely senario is that upon binding, Slit2 alters
the protein conformation of Robo4, which may lessen/abolish its
ability to interact with FN, alter a5b1 integrin intracellular
signaling, and inhibit the activation of c-Src. In addition, the
binding of Slit2 may alter also the signaling through Robo4, which
may inhibit c-Src pathway activation and lymphatic hyperperme-
ability. Although our data strongly support this model, further
investigation is needed to confirm it, or posit alternative
mechanisms for the effects of HIV-1 gp120, FN, a5b1 integrin,
Robo4 and Slit2 on lymphatic permeability.
Multiple studies indicate that the lymphatic channels play
important roles in the establishment of HIV infection, and its
dissemination throughout the host [1–4]. HIV-induced lymph-
adenopathy, including lymphoedema, is commonly seen among
HIV-infected individuals with Kaposi’s sarcoma, a vascular
neoplasm which is derived from lymphatic endothelial cells
[64,65]; however, dysfunction of the lymphatic vasculature and
its effects on HIV biology are largely unexplored. We established
an in vitro endothelial monolayer model to study the effects of HIV
on lymphatic permeability. In this model, HIV-1 gp120 and HIV-
1 virions both induced lymphatic hyperpermeability, which was
significantly inhibited by Slit2 preincubation (Figure 6B). These
results suggest key roles for gp120, FN, and Slit2/Robo4 in HIV-
associated lymphatic hyperpermeability, and implicate lymphatic
hyperpermeability in HIV infection and spread throughout the
body. Future studies to explore the traversion of HIV virions or
virus-infected cells through the lymphatic endothelium and its
contribution to HIV infection should provide more evidence on
HIV-induced lymphatic hyperpermeability and HIV dissemina-
tion in a humanized mouse model of HIV infection.
In summary, we found that the balance between HIV-1 gp120/
FN/a5b1 integrin-induced signaling and Slit2/Robo4-induced
signaling in L-LECs modulates lymphatic monolayer permeability.
Targeting these pathways may offer novel approaches to inhibit
HIV-induced lymphatic injury, and limit the dissemination of HIV
in the host.
Materials and Methods
Cells
Human embryonic kidney cells (293 cells) (Stratagene, La Jolla, CA,
USA) were cultured in Dulbecco’s modified Eagle’s medium with
10% fetal calf serum. Primary human lung lymphatic endothelial cells
(L-LECs) and dermal lymphatic endothelial cells (D-LECs) were
Figure 9. The fibronectin domains of Robo4 are critical for
gp120-induced hyperpermeability of L-LEC monolayers. (A)
Representative Western blot analysis of phosphorylated c-Src in L-LECs
pretreated with Slit2N (500 ng/ml) or a control for 1 hour, then
stimulated with fibronectin (FN) [1 mg/ml (16); 10 mg/ml (106)] for
20 minutes as indicated. GAPDH used as loading control. (B)
Permeability through an L-LEC monolayer as previously described. L-
LECs were transiently transfected with expression plasmids encoding
wild-type Robo4 (WT), mutant Robo4 (MT), or a vector control (V). After
48 hours, cells were plated for the permeability assay per manufactur-
er’s instructions. L-LEC monolayers were incubated overnight with
500 ng/ml HIV-1 gp120 or a control. Data are represented as the
percentage increase in permeability of each cell type monolayer
incubated with gp120 vs. control. Data indicate the mean 6 SD of 3
independent experiments. (*p,0.05, ***p,0.001). (C) Representative
Western blot analysis of phosphorylated c-Src and ERK1/2 in L-LECs
transiently transfected with expression plasmids encoding wild-type
Robo4 (WT), mutant Robo4 (MT), or a vector control (V). After 48 hours,
the cells were serum-starved for 2 hours and stimulated with HIV-
1gp120 (500 ng/ml) or a control for 15 minutes as indicated. GAPDH
used as loading control.
doi:10.1371/journal.ppat.1002461.g009
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EBM-2 medium with EGM-2MV SingleQuots (Lonza, Inc.).
Recombinant Proteins and HIV-1 Virions
Recombinant human Slit2N (the active fragment of Slit2) was
provided by Dr. Dean Li, Department of Oncological Sciences at
the University of Utah. The following reagents were obtained
through the AIDS Research and Reference Reagent Program,
Division ofAIDS,NIAID,NIH:recombinant HIV-1Ba-Lgp120 (M-
gp120) protein and HIV-1 virus (strain HIV-1 Ba-L, which was from
Dr. Suzanne Gartner, Dr. Mikulas Popovic and Dr. Robert Gallo).
Per NIH data sheet, HIV-1Ba-L was originally isolated from a
primary culture of adherent, human, infant lung tissue cells, and
amplified in human monocytes/macrophages. Virus was harvested
10 days post-infection. This virus was used in the transendothelial
monolayerpermeabilityassays.HIV-1gp120LAV(IIIB)(T-gp120)
was purchased from Protein Sciences Corporation (Meriden, CT,
USA). HIV-1 gp120CM was purchased from ProSpec-Tany
TechnoGene Ltd. (Ness Ziona, Israel). Src inhibitor-1 was
purchased from Sigma-Aldrich, Corp. (St. Louis, MO, USA).
Antibodies
Mouse monoclonal antibody to the HIV-1 gp120 was
purchased from Advanced Biotechnologies Inc. (Columbia, MD,
USA). Anti-integrin b1, anti-phospho-integrin b1 (Tyr783), and
neutralizing anti-integrin a5b1 antibodies were purchased from
Millipore Corp. (Billerica, MA, USA). Anti-phospho-Src kinase
family antibodies were purchased from Cell Signaling Technology,
Inc. (Beverly, MA, USA). All other antibodies were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
RT-PCR
Total cell RNA was extracted using the RNeasy Mini Kit from
Qiagen, Inc. (Valencia, CA, USA). RT-PCR was performed using
a one-step RT-PCR kit from Clontech (Mountain View, CA,
USA). Specific primers for CXCR4 and CCR5 were purchased
from R & D Systems (Minneapolis, MN, USA). The primers for
human Slit2 were synthesized by Invitrogen Corp. (Carlsbad, CA,
USA). The sequences are: upstream: 59-GGTGTCCTCTGTG-
ATGAAGAG -39; downstream: 59- GTGTTTAGGACACA-
CACCTCG -39.
Fluorescence Staining
Cells cultured in 8-well chamber slides (Thermo Fisher
Scientific Inc., Waltham, MA, USA) were fixed with 4% (v/v)
paraformaldehyde solution for 1 hour at room temperature,
incubated in fresh permeabilization solution (0.1% sodium citrate
in 1% Triton X-100 in 16PBS) for 2 minutes on ice, incubated
Figure 10. Hypothetical model for the interactions of HIV-1 gp120, FN, a5b1 integrin, Robo4 and Slit2, and their effect on the
permeability of lymphatic endothelium. Robo4 and a5b1 integrin are expressed on the surface of lymphatic endothelial cells. Under physiologic
conditions, endogenous Slit2 interacts with Robo4 via its Ig domains, and inhibits c-Src signaling. FN also interacts with Robo4 (via its FN type III
domains), and binds to a5b1 integrin on the endothelial cell surface. This contributes further to the dynamic regulation of Robo4 signaling by Slit2
and FN, to maintain the integrity of the lymphatic endothelial barrier. Upon HIV infection, gp120 significantly elevates FN levels and complexes with
FN. FN then activates a5b1 integrin, which results in enhanced intracellular signaling through a5b1 integrin, a stronger interaction between FN and
Robo4, and disruption of Robo4 signaling. These changes activate the c-Src signaling pathway and induce hyperpermeability of the lymphatic
endothelial barrier. Exogenous Slit2 may protect the lymphatic channels from HIV-induced vasculopathy by interacting with Robo4 to restore Robo4
signaling, block the c-Src pathway, and inhibit HIV-induced lymphatic hyperpermeability.
doi:10.1371/journal.ppat.1002461.g010
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human CXCR4 rabbit polyclonal antibody or normal rabbit IgG
(Millipore Corp.) at 4uC for 1 hour. The slides were then washed 3
times in 16 PBS, and incubated with a FITC-conjugated, goat
anti-rabbit IgG antibody (Vector Laboratories, Burlington, CA,
USA) at 4 uC for 30 minutes. The slides were washed again 3
times in 16PBS, and then air dried and mounted with mounting
medium (Vector Laboratories).
Vascular Permeability Assay
Lymphatic endothelial cells were seeded in the top chamber of
transwell plates, according to the manufacturer’s instructions
(Millipore Corp.), starved for one hour, and then incubated with
different reagents or their respective controls as indicated.
Subsequently, FITC-Dextran was added to the top chamber and
allowed to permeate through the monolayer to the lower chamber
for 5 minutes. The extent of permeability was determined by
measuring the fluorescence of the solution in the lower chamber
by a standard plate reader (BioTek Instruments, Inc., Vinooski,
VT, USA). The gp120 control was prepared by boiling gp120 for
10 minutes to inactivate its protein activity while preserving its
inherent endotoxin activity. It was employed here, and in all other
experiments that required a gp120 control.
Cell Stimulation, Immunoprecipitation, and Western
Blotting
Cells were starved for 2 hours in serum-free media, and then
stimulated as indicated. Cells were lysed in RIPA buffer (Cell
Signaling Technology, Inc.) after stimulation. Immunoprecipita-
tion and Western blotting were performed as described previously
[66]. For quantitation, the ratio of protein expression, phosphor-
ylation, or association vs total protein in each lane was obtained by
densitometry with a gel imaging system (Cell Biosciences, Inc.,
Santa Clara, CA, USA).
DNA Constructs
The pCMV6 Entry expression plasmid encoding Myc-DDK-
tagged Slit2 was purchased from OriGene Technologies, Inc.
(Rockville, MD, USA). The expression plasmid encoding RFP-
tagged Robo4 was constructed as follows. Robo4 cDNA was
amplified from the pCMV-SPORT6 containing Robo4 cDNA
(Thermo Fisher Scientific Inc.), using primers purchased from
Invitrogen Corp. (upstream sequence: 59-GAGGCGATCG-
CATGGGCTCTGGAGACAGCCTCCTG-39; downstream se-
quence: 59-GCGACGCGTGGAGTAATCTACAGGAGAAG-
CACCAGC-39). The purified PCR product was digested with
Sgf I plus Mlu I, and inserted into the pCMV6-AC-RFP plasmid
digested with same restriction endonucleases to create the
pCMV6-AC-RFP-Robo4. To make the mutant Robo4 expression
plasmid, we designed a pair of primers to amplify a section of the
pCMV6-AC-RFP-Robo4 plasmid by PCR. The primers are: 59-
CCCCCCCCGCTAGCTCTAGGCTTGGGGCCCTCTGCA-
GGATC-39 and 59-TTTTTTTTGCTAGCCCTGTCTGCC-
TCCTTTTAGAGCAGGCC-39. The PCR product was digested
with Nhe1, purified, and ligated with T4 DNA ligase at 16uC
overnight. The ligation product was used to transform competent
DH5 a cells. Positive clones were screened and confirmed by DNA
sequencing.
siRNA Constructs
Specific Robo4 siRNAs and control siRNAs, purchased from
Santa Cruz Biotechnology, Inc., were used to transfect L-LECs
using HiPerFect transfection reagent from Qiagen, Inc.
Plasmid DNA Transfection
Cells were grown to 60% confluence in tissue culture dishes.
Transfections were done using Super Effectene transfection
reagent according to the manufacturer’s instructions (Qiagen,
Inc.). At 3 hours post-transfection, cells were washed once with 16
PBS, then cultured in full medium for 48 hours. The transfection
efficiency was determined by detection of red fluorescent cells
under a fluorescent microscope (Nikon Diaphot 300, Tokyo,
Japan).
Confocal Microscopy
Cells cultured in 8-well chamber slides (Thermo Fisher
Scientific Inc.) were serum starved for 2 hours, and then treated
with HIV-1 gp120 as indicated. Subsequently, cells were fixed
with 4% (v/v) paraformaldehyde for at least 1 hour at room
temperature and permeabilized for 2 minutes on ice. Cells were
then incubated with primary antibodies or normal IgG controls
overnight at 4uC, and washed 3 times with 16PBS. Fluorescence-
conjugated secondary antibodies were added for 30 minutes at
4uC and the cells were washed 3 times in 16 PBS. Finally, the
chambers were removed and coverslips were affixed with
mounting medium containing DAPI (Vector Laboratories). Slides
were examined under a Leica TCS-NT laser scanning confocal
microscope (Leica Microsystems, Bannockburn, IL, USA).
Data Analysis
Each experiment was repeated at least 3 times, and represen-
tative blots, images, or graphs are shown in the figures. Statistical
significance was determined using the ANOVA test (*p,0.05).
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